Defibrotide lowers rates of veno-occlusive disease after transplant

02/24/2012 | DoctorsLounge.com

Defibrotide prophylaxis can reduce cases of hepatic veno-occlusive disease among patients younger than 18 undergoing hematopoietic stem cell transplantation, German researchers found. The study in The Lancet journal showed that 12% of patients who received the drug developed veno-occlusive disease 30 days after transplantation, compared with 20% in the control group.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA